Checkmate Pharmaceuticals (NASDAQ:CMPI) reported quarterly losses of $(0.88) per share. This is a 88.06 percent increase over losses of $(7.37) per share from the same period last year.
Akari Therapeutics Announced 15M ADS Registered Direct Offering Priced @$0.85/ADS
Akari Therapeutics, Plc (Nasdaq: AKTX) today announced it has entered into definitive agreements with healthcare-focused institutional investors alongside participation from certain existing investors, including the Akari Executive Chairman of the Board of Directors, Dr.
